Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2% - What's Next?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) traded up 5.2% during trading on Thursday . The stock traded as high as $3.42 and last traded at $3.42. 1,043,397 shares were traded during mid-day trading, a decline of 39% from the average session volume of 1,719,907 shares. The stock had previously closed at $3.25.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on XERS. HC Wainwright upped their price target on Xeris Biopharma from $6.00 to $6.60 and gave the stock a "buy" rating in a research report on Monday, November 11th. Piper Sandler lowered shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price objective on the stock. in a research report on Monday, November 11th.

Xeris Biopharma Price Performance

The firm has a market cap of $508.37 million, a price-to-earnings ratio of -7.58 and a beta of 2.65. The business has a 50-day moving average of $3.24 and a 200-day moving average of $2.77.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Goldstein Advisors LLC raised its holdings in shares of Xeris Biopharma by 19.7% in the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company's stock valued at $87,000 after purchasing an additional 5,000 shares during the period. The Manufacturers Life Insurance Company increased its position in Xeris Biopharma by 10.1% during the second quarter. The Manufacturers Life Insurance Company now owns 57,805 shares of the company's stock worth $130,000 after buying an additional 5,291 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Xeris Biopharma by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company's stock worth $82,000 after buying an additional 11,239 shares during the last quarter. Rhumbline Advisers raised its stake in Xeris Biopharma by 6.9% in the second quarter. Rhumbline Advisers now owns 189,970 shares of the company's stock valued at $427,000 after buying an additional 12,332 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Xeris Biopharma in the third quarter valued at approximately $35,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.